Priya P. Chan
No Rating Available
(Learn About Our Rating System)

Priya P. Chan, MD

Languages spoken: English

Clinical Locations

Primary Location

Primary Children's Hospital

Hematology/Oncology
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
801-662-4799
Get Directions

Dr. Chan received her medical degree from the University of Minnesota Medical School, completed her Pediatric Residency at the University of Wisconsin, and her Pediatric Hematology/Oncology Fellowship at the University of Utah. Following fellowship she completed a Pediatric Neuro-Oncology Fellowship at the University of Colorado/Children’s Hospital Colorado.

Dr. Chan is currently an Assistant Professor of Pediatrics at the University of Utah in the Division of Pediatric Hematology/Oncology. She is a member of the neuro-oncology team at Primary Children’s Medical Center.

Dr. Chan’s clinical interests include the care of children and young adults with brain and spine tumors. Dr. Chan’s research interests are focused on the development of early phase clinical trials for children with central nervous system tumors and the long-term care of patients who have survived these cancers.

Specialties

Board Certification

American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Dr. Chan received her medical degree from the University of Minnesota Medical School, completed her Pediatric Residency at the University of Wisconsin, and her Pediatric Hematology/Oncology Fellowship at the University of Utah. Following fellowship she completed a Pediatric Neuro-Oncology Fellowship at the University of Colorado/Children’s Hospital Colorado.

Dr. Chan is currently an Assistant Professor of Pediatrics at the University of Utah in the Division of Pediatric Hematology/Oncology. She is a member of the neuro-oncology team at Primary Children’s Medical Center.

Dr. Chan’s clinical interests include the care of children and young adults with brain and spine tumors. Dr. Chan’s research interests are focused on the development of early phase clinical trials for children with central nervous system tumors and the long-term care of patients who have survived these cancers.

Board Certification and Academic Information

Academic Departments Pediatrics -Assistant Professor (Clinical)
Academic Divisions Hematology/Oncology
Board Certification
American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Education history

Undergraduate Neuroscience - Johns Hopkins University B.A.
Professional Medical Medicine - University of Minnesota Medical School M.D.
Residency Pediatrics, Global Health Track - University of Wisconsin School of Medicine and Public Health Intern/Resident
Fellowship Pediatric Hematology-Oncology - University of Utah School of Medicine Fellow
Fellowship Pediatric Neuro-Oncology - University of Colorado School of Medicine Fellow

Selected Publications

Journal Article

  1. Chan PP, Sabus A, Hemenway S, Chatfield KC, White CJ, Mirsky DM, Foreman NK, Dahl N (2023). Thromboemoblic Toxicity Observed with Concurrent Trametiib and Lenalidomide Therapy. Pediatric Blood and Cancer, 70(3), e30190.
  2. Casey MJ, Chan PP, Li Q, Zu JF, Jette CA, Kohler M, Myers BR, Stewart R (2024). A simple and scalable zebrafish model of Sonic hedgehog medulloblastoma. Cell reports, 43(8), 114559.
  3. Chan PP, Whipple NS, Ramani B, Solomon DA, Zhou H, Linscott LL, Kestle JRW, Bruggers C (2023). Patterns of Extraneural Metastases in Children With Ependymoma. Journal of pediatric hematology/oncology, 45(2), e272-e278.
  4. Pratt D, Lucas CG, Selvam PP, Abdullaev Z, Ketchum C, Quezado M, Armstrong TS, Gilbert MR, Papanicolau-Sengos A, Raffeld M, Choo-Wosoba H, Chan P, Whipple N, Nasrallah M, Santi M, Ramaswamy V, Giannini C, Ritzmann TA, Grundy RG, Burford A, Jones C, Hawkins C, Venneti S, Solomon DA, Aldape (2022). Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta neuropathologica, 144(2), 373-376.

Letter

  1. Shyr DC, Homsombath AA, Chan PP, Boyer MW, Harris AC (2020). Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia [Letter to the editor]. Pediatr Blood Cancer, 67(4), e28155.